PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35216791-1	2022	Fingolimod treatment has been associated with opportunistic infections, most notably PML and cryptococcal meningitis.	Fingolimod Hydrochloride	0-10	PML nuclear body scaffold	Homo sapiens	85-88	
33272956-0	2021	Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.	Fingolimod Hydrochloride	71-81	PML nuclear body scaffold	Homo sapiens	93-96	
29985084-5	2019	The adjusted odds ratio of PML for each drug was as follows; natalizumab 115.72 (95% CI; 83.83, 159.74), fingolimod 4.98 (3.64, 6.81) followed by dimethyl fumarate 1.77 (1.2, 2.62) and rituximab 3.22 (1.07, 9.72).	Fingolimod Hydrochloride	105-115	PML nuclear body scaffold	Homo sapiens	27-30	
29985084-8	2019	CONCLUSION: The reporting proportion of PML was relatively higher in natalizumab followed by fingolimod, dimethyl fumarate and rituximab.	Fingolimod Hydrochloride	93-103	PML nuclear body scaffold	Homo sapiens	40-43	
29532286-9	2018	Fingolimod treatment is likely to increase serum JCVAb index, possibly leading to the development of PML.	Fingolimod Hydrochloride	0-10	PML nuclear body scaffold	Homo sapiens	101-104	
28283109-4	2017	Fingolimod and dimethyl fumarate have also been unquestionably associated with a risk of PML in the MS population.	Fingolimod Hydrochloride	0-10	PML nuclear body scaffold	Homo sapiens	89-92	
27164718-0	2016	Fingolimod-associated PML in a patient with prior immunosuppression.	Fingolimod Hydrochloride	0-10	PML nuclear body scaffold	Homo sapiens	22-25